Laboratory of Experimental Hematology, Institute of Biophysics, v.v.i., Academy of Sciences of the Czech Republic, Královopolská 135, CZ-61265 Brno, Czech Republic.
Radiat Res. 2011 Aug;176(2):269-72. doi: 10.1667/rr2614.1. Epub 2011 Jun 10.
This study extends earlier findings of the authors demonstrating that meloxicam, a selective inhibitor of cyclooxygenase 2, supports hematopoietic recovery in sublethally irradiated mice and is radioprotective when given before irradiation. We report here that when meloxicam was administered in a single dose 1 h after a lethal 9-Gy whole-body dose, an increased 30-day survival was achieved. Additional studies showed that administration of meloxicam 24 h after lethal irradiation is ineffective and its repeated administration deleterious. Possible mechanisms of the therapeutic effects of meloxicam administered early after irradiation are discussed.
本研究扩展了作者先前的发现，证明美洛昔康（一种环氧化酶 2 的选择性抑制剂）可支持亚致死剂量辐射的小鼠造血恢复，并且在照射前给药具有放射防护作用。我们在此报告，当在致死剂量 9 Gy 全身照射后 1 小时给予单次剂量的美洛昔康时，可实现 30 天存活率的提高。进一步的研究表明，在致死照射后 24 小时给予美洛昔康是无效的，并且其重复给药是有害的。讨论了照射后早期给予美洛昔康的治疗效果的可能机制。
